Julikang Nabbed Tens of Millions of Yuan in B Round Financing, Led by Highlight Capital

According to PEdaily, Julikang Sterilization Technology Co. LTD (Julikang) announced that it had completed tens of millions of yuan Series B financing, led by Highlight Capital. This round of financing will be mainly used for the construction of the new medical disinfection supply center and the upgrade and transformation of the existing center, as well as the information system.

Founded in 2010, Julikang is a medical institution focusing on third-party disinfection. At present, it has medical disinfection supply centers in Shanghai, Tianjin, Guangzhou, Anhui, Fujian, Shanxi, Chongqing, Liaoning, Henan, and other provinces. The company cooperates with hospitals and hundreds of medical device companies.

The team of Julikang has rich experience in disinfection supply center design, production, quality control, logistics, software development and so on. In the past year, Julikang had completed the upgrade of existing centers and the application of the practice license before the new industrial rule was carried out. It has built three new centers and accomplished the construction of its first intelligent disinfection supply center.

"Julikang has accumulated rich experience in third-party disinfection supply and achieved the goal of reducing costs and increasing efficiency for hospitals so that hospitals can focus more on medical care. Such a company with long-term value is always respected by our fund. We hope this financing will help the company continue to grow and provides sterilizing supplies for more healthcare facilities," said Wu Jin, the partner of Highlight Capital.

HLC is a health industry focused fund. It is dedicated to investing in leading life science enterprises that provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. With extensive experience, the company has established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO, etc.), medical technology (medical devices, IVD, etc.) and consumer health (hospital chains, personal care, etc.).